We and others have shown that the knockdown of MCL-1 sensitizes melanoma cells to various treatments, including BRAF or MEK inhibitors [19–23] and thus, targeting MCL-1 can be a new alternative for melanoma treatment. This evidence concerns the gene MAP2K7 and melanoma.